RARE diseases specialist pharmaceutical company Alexion has announced it has made a public cash offer to the shareholders of Wilson Therapeutics, a research company with a copper toxicity disease focus, to acquire all outstanding shares in the company.
The deal is valued at around AU$1.1 billion.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Apr 18
